GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (NAS:GNPX) » Definitions » Total Current Assets

Genprex (Genprex) Total Current Assets : $9.23 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Genprex Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Genprex's total current assets for the quarter that ended in Mar. 2024 was $9.23 Mil.


Genprex Total Current Assets Historical Data

The historical data trend for Genprex's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex Total Current Assets Chart

Genprex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Assets
Get a 7-Day Free Trial Premium Member Only 2.98 27.70 39.14 21.47 7.53

Genprex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.94 12.37 12.86 7.53 9.23

Genprex Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Genprex's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Genprex's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Genprex  (NAS:GNPX) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Genprex's Liquidation Value for the quarter that ended in Mar. 2024 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=8.217-3.808+0.75 * 0+0.5 * 0
=4.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genprex Total Current Assets Related Terms

Thank you for viewing the detailed overview of Genprex's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Genprex (Genprex) Business Description

Traded in Other Exchanges
Address
3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company. It is a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.
Executives
Catherine M Vaczy officer: EVP & Chief Strategy Officer C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
John Rodney Varner director, 10 percent owner, officer: Chief Executive Officer P.O. BOX 162341, AUSTIN TX 78716
Hermant Kumar officer: Chief Mfgr & Tech Officer 3300 BEE CAVE ROAD, #650-227, AUSTIN TX 78746
Mark Stanley Berger officer: Chief Medical Officer 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Brent M Longnecker director C/O RESOURCES CONNECTION, 695 TOWN CENTER DR, COSTA MESA CA 92626
Moreno Toscano Jose Antonio director 1501 UNIVERSITY CLUB DRIVE, AUSTIN TX 78732
Wilson William R Jr. director 1407 ETHRIDGE AVE, AUSTIN TX 78703
Michael Thomas Redman officer: EVP & Chief Operating Officer 16402 EMILIA COURT, SPRING TX 77379
John N Bonfiglio director C/O MICROLIN BIO, INC., NEW YORK NY 10022
Genprex, Inc. director, 10 percent owner, officer: Chief Executive Officer 1601 TRINITY STREET, BLDG. B, SUITE 3.322, AUSTIN TX 78712
Julien L Pham officer: Chief Operating Officer 944 DORCHESTER AVE #56, BOSTON MA 02125
Jack A Roth 10 percent owner 6516 BROMPTON ROAD, HOUSTON TX 770055
Christy M. Nance 10 percent owner 8305 SCENIC RIDGE COVE, AUSTIN TX 78735
Ryan M. Confer officer: Chief Financial Officer 1000 SAN MARCOS ST. #460, AUSTIN TX 78702
Robert W. Pearson director 3001 MEANDERING RIVER COURT, AUSTIN TX 78746

Genprex (Genprex) Headlines

From GuruFocus

Genprex to Present at Upcoming December Investor Conference

By PRNewswire PRNewswire 12-02-2022